Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-small Cell Lung Cancer NSCLC × olaparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 93 Breast Neoplasms 69 Prostatic Neoplasms 34 Triple Negative Breast Neoplasms 32 Neoplasms 26 Fallopian Tube Neoplasms 25 Neoplasm Metastasis 21 Pancreatic Neoplasms 19 Endometrial Neoplasms 19 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 12 Carcinoma, Non-Small-Cell Lung 10 Stomach Neoplasms 9 Sarcoma 9 Recurrence 9 Lung Neoplasms 9 Fanconi Anemia, Complementation Group D1 9 Squamous Cell Carcinoma of Head and Neck 8 Glioma 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Glioblastoma 7 Colorectal Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 5 Lymphoma, Non-Hodgkin 5 Cholangiocarcinoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Solid Tumors 4 Osteosarcoma 4

Interventions

olaparib 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03775486 2026-02-10

ORION

AstraZeneca

Phase 2 Active not recruiting

401 enrolled 26 charts

Non-small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡